The A-share innovative drug sector rebounded during the session, with Northland rising nearly 20%. Previously, Huasen Pharmaceutical and Haixin Pharmaceutical hit their daily limit, while Haoyuan Pharmaceutical, Zhaoyan New Drug, Changshan Pharmaceutical, and Shouyao Holdings followed suit.